3.0.0 3204 2023-03-22T18:49:18Z 2023-03-22T18:49:18Z House H HR 2013-09-27 113 From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. UPTON:H.R. 3204.Congress has the power to enact this legislation pursuantto the following:This bill is enacted pursuant to the power granted toCongress under Article I, Section 8, Clause 3 of the UnitedStates Constitution. (Commerce Clause)[Page H5922]]]> hsif00 Energy and Commerce Committee House Standing Referred to 2013-09-27T13:01:35Z Safeguarding America's Pharmaceuticals Act of 2013 113 1919 HR 2013-06-04 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS Drug Supply Chain Security Act 113 957 S 2013-05-15 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS Pharmaceutical Quality, Security, and Accountability Act 113 959 S 2013-06-19 Placed on Senate Legislative Calendar under General Orders. Calendar No. 89. Related bill CRS 2013-11-27 Became Public Law No: 113-54. President E40000 2 House floor actions 2013-11-27 Became Public Law No: 113-54. BecameLaw 36000 9 Library of Congress 2013-11-27 Signed by President. President E30000 2 House floor actions 2013-11-27 Signed by President. BecameLaw 36000 9 Library of Congress 2013-11-21 Presented to President. Floor E20000 2 House floor actions 2013-11-21 Presented to President. President 28000 9 Library of Congress 2013-11-18 Senate Message on Senate action sent to the House. Floor 2013-11-18 Senate Passed Senate without amendment by Voice Vote. Floor 2013-11-18 Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. Floor 17000 9 Library of Congress 2013-11-18 sshr00 Health, Education, Labor, and Pensions Committee Senate Motion by Senator Reid to commit to Senate Committee on Health, Education, Labor, and Pensions with instructions to report back forthwith with amendment SA 2035 withdrawn in Senate. (consideration: CR S8071) Floor 2013-11-18 Senate Cloture motion withdrawn by unanimous consent in Senate. (consideration: CR S8071) Floor 2013-11-18 Senate Considered by Senate. (consideration: CR S8071-8076) Floor 2013-11-14 Senate Cloture motion on the measure presented in Senate. (consideration: CR S8027; text: CR S8027) Floor 2013-11-14 sshr00 Health, Education, Labor, and Pensions Committee Senate Motion by Senator Reid to commit to Senate Committee on Health, Education, Labor, and Pensions with instructions to report back forthwith with amendment SA 2035 made in Senate. (consideration: CR S8026; text: CR S8026) Floor 2013-11-14 Senate Measure laid before Senate by motion. (consideration: CR S8026, S8027) Floor 2013-11-14 Senate Motion to proceed to consideration of measure agreed to in Senate by Voice Vote. Floor 2013-11-13 Senate Motion to proceed to measure considered in Senate. (consideration: CR S7973-7996) Floor 2013-11-12 Senate Cloture on the motion to proceed to the measure invoked in Senate by Yea-Nay Vote. 97 - 1. Record Vote Number: 234. (consideration: CR S7949-7950; text: CR S7949) Floor 234 https://www.senate.gov/legislative/LIS/roll_call_votes/vote1131/vote_113_1_00234.xml Senate 113 2013-11-12T23:20:42Z 1 2013-11-12 Senate Motion to proceed to consideration of measure made in Senate. (consideration: CR S7949-7950) Floor 2013-11-07 Senate Cloture motion on the motion to proceed to the measure presented in Senate. (consideration: CR S7923-7924; text: CR S7923-7924) Floor 2013-11-07 Senate Motion to proceed to consideration of measure made in Senate. (consideration: CR S7891-7894, S7909-7920, S7923-7924) Floor 2013-11-06 Senate Motion to proceed to consideration of measure withdrawn in Senate. (consideration: CR S7864) Floor 2013-11-06 Senate Motion to proceed to consideration of measure made in Senate. (consideration: CR S7841-7845, S7846-7864) Floor 2013-11-05 Senate Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 236. Calendars 2013-11-04 Senate Read the first time. Placed on Senate Legislative Calendar under Read the First Time. Calendars 2013-09-30 Senate Received in the Senate. IntroReferral 2013-09-28 14:34:53 On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5946-5960) Floor H37300 2 House floor actions 2013-09-28 14:34:53 Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H5946-5960) Floor 8000 9 Library of Congress 2013-09-28 13:48:27 DEBATE - The House proceeded with forty minutes of debate on H.R. 3204. Floor H8D000 2 House floor actions 2013-09-28 13:48:25 Considered under suspension of the rules. (consideration: CR H5946-4965) Floor H30000 2 House floor actions 2013-09-28 13:48:15 Mr. Upton moved to suspend the rules and pass the bill. Floor H30300 2 House floor actions 2013-09-27 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2013-09-27 Introduced in House IntroReferral Intro-H 9 Library of Congress 2013-09-27 Introduced in House IntroReferral 1000 9 Library of Congress U000031 Rep. Upton, Fred [R-MI-6] FRED UPTON R MI 6 N W000215 Rep. Waxman, Henry A. [D-CA-33] HENRY WAXMAN D CA A. 33 2013-09-27 True P000373 Rep. Pitts, Joseph R. [R-PA-16] JOSEPH PITTS R PA R. 16 2013-09-27 True P000034 Rep. Pallone, Frank, Jr. [D-NJ-6] FRANK PALLONE D NJ 6 2013-09-27 True M001151 Rep. Murphy, Tim [R-PA-18] Tim Murphy R PA 18 2013-09-27 True D000355 Rep. Dingell, John D. [D-MI-12] JOHN DINGELL D MI D. 12 2013-09-27 True L000566 Rep. Latta, Robert E. [R-OH-5] Robert Latta R OH E. 5 2013-09-27 True D000197 Rep. DeGette, Diana [D-CO-1] DIANA DEGETTE D CO 1 2013-09-27 True G000568 Rep. Griffith, H. Morgan [R-VA-9] H. Griffith R VA Morgan 9 2013-09-27 True G000410 Rep. Green, Gene [D-TX-29] GENE GREEN D TX 29 2013-09-27 True M001142 Rep. Matheson, Jim [D-UT-4] JIM MATHESON D UT 4 2013-09-27 True Public Law 113-54 Health Administrative law and regulatory procedures Administrative remedies Advisory bodies Business records Computers and information technology Congressional oversight Consumer affairs Department of Health and Human Services Drug safety, medical device, and laboratory regulation Federal preemption Food and Drug Administration (FDA) Government information and archives Government studies and investigations Licensing and registrations Manufacturing Marketing and advertising Prescription drugs Public participation and lobbying Retail and wholesale trades Technology assessment Trade secrets and economic espionage User charges and fees Health 00 2013-09-27 Introduced in House 2013-11-07T19:21:12Z Drug Quality and Security Act - Compounding Quality Act - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs. Exempts compounded drugs from new drug requirements, labeling requirements, and track and trace requirements if the drug is compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility and meets applicable requirements.

Establishes annual registration requirement for any outsourcing facility. Requires a facility to report biannually to the Secretary of Health and Human Services on what drugs are compounded in the facility and to submit adverse event reports. Subjects such facilities to a risk-based inspection schedule.

Requires the Secretary to: (1) publish a list of drugs presenting demonstrable difficulties for compounding that are reasonably likely to lead to an adverse effect on the safety or effectiveness of the drug, taking into account the risk and benefits to patients; and (2) convene an advisory committee on compounding before creating the list.

Requires the Secretary to assess an annual establishment fee on each outsourcing facility and a reinspection fee, as necessary.

Prohibits the resale of a compounded drug labeled “not for resale,” or the intentional falsification of a prescription for a compounded drug. Deems a drug to be misbranded if the advertising or promotion of a compounded drug is false or misleading in any particular.

Requires the Secretary to receive submissions from state boards of pharmacy: (1) describing any disciplinary actions taken against compounding pharmacies or any recall of a compounded drug, and (2) expressing concerns that a compounding pharmacy may be violating the FFDCA.

Revises compounding pharmacy requirements to remove prohibitions on advertising and promotion by compounding pharmacies and remove requirement that prescriptions filled by a compounding pharmacy be unsolicited.

Requires the Comptroller General (GAO) to report on pharmacy compounding and the adequacy of state and federal efforts to assure the safety of compounded drugs.

Drug Supply Chain Security Act - Establishes requirements to facilitate the tracing of prescription drug products through the pharmaceutical supply distribution chain.

Requires the Secretary to establish standards for the exchange of transaction documentation, which shall include transaction information, transaction history, and transaction statements.

Requires the Secretary to establish processes to: (1) provide waivers of requirements, including for undue economic hardship or emergency medical reasons; (2) provide exceptions to requirements relating to product identifiers if a product is packaged without sufficient space to bear the information; and (3) determine other products or transactions that should be exempt from the requirements of this Act.

Establishes requirements for drug manufacturers, wholesalers, dispensers, and repackagers to ensure that all prior transaction information is provided at each transfer of ownership.

Requires a manufacturer, wholesale distributor, dispenser, and repackager, in the event of a recall or for the purpose of investigating a suspect product or an illegitimate product, to provide within a reasonable time the applicable transaction documentation upon request by the Secretary or other appropriate federal or state official.

Requires a manufacturer or repackager to affix or imprint a product identifier on each package and homogenous case intended to be introduced in a transaction into commerce except for products that are required to have a standardized numerical identifier.

Requires a manufacturer, wholesale distributor, dispenser, or repackager to ensure that each of its trading partners is authorized.

Requires a manufacturer, wholesale distributor, dispenser, and repackager to implement systems to: (1) investigate suspect products; and (2) handle illegitimate products, including through quarantine, disposal, and appropriate notice to the Secretary and, as necessary, trading partners.

Requires manufacturers, wholesale distributors, and repackagers to verify returned products before further distribution.

Implements additional requirements related to the tracing of products at the package level ten years after enactment of this Act.

Requires the Secretary to establish projects and hold public meetings to enhance the safety and security of the pharmaceutical distribution supply chain.

Requires the Secretary to establish standards for the licensing of wholesale distributors and third party logistics providers.

Preempts state and local requirements related to tracing drugs through the distribution system, and licensure of wholesale distributors and third party logistics providers.

]]> 49 2013-11-27 Public Law 2014-01-24T16:43:25Z (This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

Drug Quality and Security Act - Title I: Drug Compounding - Compounding Quality Act - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs. Exempts compounded drugs from new drug requirements, labeling requirements, and track and trace requirements if the drug is compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility and meets applicable requirements.

Establishes annual registration requirement for any outsourcing facility. Requires a facility to report biannually to the Secretary of Health and Human Services (HHS) on what drugs are compounded in the facility and to submit adverse event reports. Subjects such facilities to a risk-based inspection schedule.

Requires the Secretary to: (1) publish a list of drugs presenting demonstrable difficulties for compounding that are reasonably likely to lead to an adverse effect on the safety or effectiveness of the drug, taking into account the risk and benefits to patients; and (2) convene an advisory committee on compounding before creating the list.

Requires the Secretary to assess an annual establishment fee on each outsourcing facility and a reinspection fee, as necessary.

(Sec. 103) Prohibits the resale of a compounded drug labeled “not for resale,” or the intentional falsification of a prescription for a compounded drug. Deems a compounded drug to be misbranded if its advertising or promotion is false or misleading in any particular.

(Sec. 105) Requires the Secretary to receive submissions from state boards of pharmacy: (1) describing any disciplinary actions taken against compounding pharmacies or any recall of a compounded drug, and (2) expressing concerns that a compounding pharmacy may be violating the FFDCA.

(Sec. 106) Revises compounding pharmacy requirements to repeal prohibitions on advertising and promotion of compounded drugs by compounding pharmacies and repeal the requirement that prescriptions filled by a compounding pharmacy be unsolicited.

(Sec. 107) Requires the Comptroller General (GAO) to report on pharmacy compounding and the adequacy of state and federal efforts to assure the safety of compounded drugs.

Title II: Drug Supply Chain Security - Drug Supply Chain Security Act - (Sec. 202) Establishes requirements to facilitate the tracing of prescription drug products through the pharmaceutical supply distribution chain.

Requires the Secretary to establish standards for the exchange of transaction documentation, which shall include transaction information, transaction history, and transaction statements.

Requires the Secretary to establish processes to: (1) provide waivers of requirements, including for undue economic hardship or emergency medical reasons; (2) provide exceptions to requirements relating to product identifiers if a product is packaged without sufficient space to bear the information; and (3) determine other products or transactions that should be exempt from the requirements of this Act.

Establishes requirements for drug manufacturers, wholesalers, dispensers, and repackagers to ensure that all prior transaction information is provided at each transfer of ownership.

Requires a manufacturer, wholesale distributor, dispenser, and repackager, in the event of a recall or for the purpose of investigating a suspect product or an illegitimate product, to provide within a reasonable time the applicable transaction documentation upon request by the Secretary or other appropriate federal or state official.

Requires a manufacturer or repackager to affix or imprint a product identifier on each package and homogenous case intended to be introduced in a transaction into commerce. Excepts from this requirement with respect to unique device identifiers any products required to have a standardized numerical identifier.

Requires a manufacturer, wholesale distributor, dispenser, or repackager to ensure that each of its trading partners is authorized.

Requires a manufacturer, wholesale distributor, dispenser, and repackager to implement systems to: (1) investigate suspect products; and (2) handle illegitimate products, including through quarantine, disposal, and appropriate notice to the Secretary and, as necessary, trading partners.

Requires manufacturers, wholesale distributors, and repackagers to verify returned products before further distribution.

(Sec. 203) Prescribes additional requirements related to the tracing of products at the package level (enhanced drug distribution security) which shall go into effect ten years after enactment of this Act.

Authorizes a dispenser to enter into a written agreement with a third party, including an authorized wholesale distributor, that requires the third party to maintain confidentially any information and statements required to be maintained. Requires the Secretary to provide for alternative methods of compliance with such additional drug distribution security requirements.

Directs the Secretary to contract with a private, independent consulting firm with expertise to conduct a technology and software assessment that looks at the feasibility of dispensers with 25 or fewer full-time employees conducting interoperable, electronic tracing of products at the package level.

Requires the Secretary to: (1) establish one or more pilot projects and hold public meetings to enhance the safety and security of the pharmaceutical distribution supply chain, (2) issue a final guidance document that outlines and makes recommendations with respect to the system attributes necessary to enable secure tracing at the package level, and (3) identify and make recommendations with respect to the standards necessary for adoption in order to support the secure interoperable electronic data exchange among the pharmaceutical distribution supply chain that comply with a form and format developed by a widely recognized international standards development organization.

(Sec. 204) Requires the Secretary to establish standards for the licensing of wholesale distributors and third party logistics providers.

(Sec. 205) Preempts state and local requirements related to tracing drugs through the distribution system, and licensure of wholesale distributors and third party logistics providers.

(Sec. 206) Subjects violations of this Act to specified criminal and civil penalties.

Deems misbranded any drug failing to bear its required product identifier.

]]> Drug Quality and Security Act Display Title Drug Quality and Security Act Official Title as Introduced To amend the Federal Food, Drug, and Cosmetic Act with respect to human drug compounding and drug supply chain security, and for other purposes. Introduced in House IH Short Titles as Passed Senate for portions of this bill Drug Supply Chain Security Act S Senate Short Titles as Passed House for portions of this bill Drug Supply Chain Security Act H House Short Titles as Passed Senate for portions of this bill Compounding Quality Act S Senate Short Titles as Enacted for portions of this bill Drug Supply Chain Security Act Short Titles as Enacted for portions of this bill Compounding Quality Act Short Titles as Passed House Drug Quality and Security Act H House Short Titles as Enacted Drug Quality and Security Act Short Titles as Passed Senate Drug Quality and Security Act S Senate Short Titles as Passed House for portions of this bill Compounding Quality Act H House Short Titles as Introduced Drug Quality and Security Act 2037 113 SAMDT Of a perfecting nature. 2022-02-08T17:32:01Z 2013-11-18 SA 2037 fell when SA 2036 fell. (consideration: CR S8071) S8071 https://www.congress.gov/congressional-record/volume-159/senate-section/page/S8071 SA 2036 https://www.congress.gov/amendment/113th-congress/senate-amendment/2036 SA 2037 https://www.congress.gov/amendment/113th-congress/senate-amendment/2037 R000146 Sen. Reid, Harry [D-NV] HARRY REID D NV M. 2013-11-14T05:00:00Z 2013-11-14T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2036 113 SAMDT Of a perfecting nature. 2022-02-08T17:32:01Z 6 2013-11-18 0 Senate SA 2037 fell when SA 2036 fell. (consideration: CR S8071) Floor 2013-11-18 0 Senate Considered by Senate. (consideration: CR S8071) Floor 2013-11-14 0 Senate Amendment SA 2037 proposed by Senator Reid to Amendment SA 2036. (consideration: CR S8026; text: CR S8026) Of a perfecting nature. Floor 2013-11-14 Senate amendment proposed (on the floor): Amendment SA 2037 proposed by Senator Reid to Amendment SA 2036.(consideration: CR S8026; text: CR S8026) Floor 93000 9 Library of Congress 2013-11-14 Senate amendment submitted Floor 91000 9 Library of Congress 2036 113 SAMDT Of a perfecting nature. 2022-02-08T17:32:01Z 2013-11-18 SA 2036 fell when SA 2035 withdrawn. (consideration: CR S8071) S8071 https://www.congress.gov/congressional-record/volume-159/senate-section/page/S8071 SA 2035 https://www.congress.gov/amendment/113th-congress/senate-amendment/2035 SA 2036 https://www.congress.gov/amendment/113th-congress/senate-amendment/2036 R000146 Sen. Reid, Harry [D-NV] HARRY REID D NV M. 2013-11-14T05:00:00Z 2013-11-14T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2035 113 SAMDT To change the enactment date. 2022-02-08T17:32:01Z 1 6 2013-11-18 0 Senate SA 2036 fell when SA 2035 withdrawn. (consideration: CR S8071) Floor 2013-11-18 0 Senate Considered by Senate. (consideration: CR S8071) Floor 2013-11-14 0 Senate Amendment SA 2036 proposed by Senator Reid to Amendment SA 2035 (the instructions of the motion to commit). (consideration: CR S8026; text: CR S8026) Of a perfecting nature. Floor 2013-11-14 Senate amendment proposed (on the floor): Amendment SA 2036 proposed by Senator Reid to Amendment SA 2035 (the instructions of the motion to commit).(consideration: CR S8026; text: CR S8026) Floor 93000 9 Library of Congress 2013-11-14 Senate amendment submitted Floor 91000 9 Library of Congress 2035 113 SAMDT To change the enactment date. 2022-02-08T17:32:01Z 2013-11-18 Proposed amendment SA 2035 withdrawn in Senate. (consideration: CR S8071) S8071 https://www.congress.gov/congressional-record/volume-159/senate-section/page/S8071 SA 2035 https://www.congress.gov/amendment/113th-congress/senate-amendment/2035 R000146 Sen. Reid, Harry [D-NV] HARRY REID D NV M. 2013-11-14T05:00:00Z 2013-11-14T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 1 6 2013-11-18 0 Senate Proposed amendment SA 2035 withdrawn in Senate. (consideration: CR S8071) Floor 2013-11-18 0 Senate Considered by Senate. (consideration: CR S8071) Floor 2013-11-14 0 Senate Amendment SA 2035 proposed by Senator Reid. (consideration: CR 8026; text: CR 8026) To change the enactment date. Floor 2013-11-14 Senate amendment proposed (on the floor): Amendment SA 2035 proposed by Senator Reid.(consideration: CR 8026; text: CR 8026) Floor 93000 9 Library of Congress 2013-11-14 Senate amendment submitted Floor 91000 9 Library of Congress 2034 113 SAMDT Of a perfecting nature. 2022-02-08T17:32:01Z 2013-11-18 SA 2034 fell when SA 2033 withdrawn. (consideration: CR S8071) S8071 https://www.congress.gov/congressional-record/volume-159/senate-section/page/S8071 SA 2033 https://www.congress.gov/amendment/113th-congress/senate-amendment/2033 SA 2034 https://www.congress.gov/amendment/113th-congress/senate-amendment/2034 R000146 Sen. Reid, Harry [D-NV] HARRY REID D NV M. 2013-11-14T05:00:00Z 2013-11-14T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2033 113 SAMDT To change the enactment date. 2022-02-08T17:32:01Z 6 2013-11-18 0 Senate SA 2034 fell when SA 2033 withdrawn. (consideration: CR S8071) Floor 2013-11-18 0 Senate Considered by Senate. (consideration: CR S8071) Floor 2013-11-14 0 Senate Amendment SA 2034 proposed by Senator Reid to Amendment SA 2033. (consideration: CR 8026; text: CR 8026) Of a perfecting nature. Floor 2013-11-14 Senate amendment proposed (on the floor): Amendment SA 2034 proposed by Senator Reid to Amendment SA 2033.(consideration: CR 8026; text: CR 8026) Floor 93000 9 Library of Congress 2013-11-14 Senate amendment submitted Floor 91000 9 Library of Congress 2033 113 SAMDT To change the enactment date. 2022-02-08T17:32:01Z 2013-11-18 Proposed amendment SA 2033 withdrawn in Senate. (consideration: CR S8071) S8071 https://www.congress.gov/congressional-record/volume-159/senate-section/page/S8071 SA 2033 https://www.congress.gov/amendment/113th-congress/senate-amendment/2033 R000146 Sen. Reid, Harry [D-NV] HARRY REID D NV M. 2013-11-14T05:00:00Z 2013-11-14T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 1 6 2013-11-18 0 Senate Proposed amendment SA 2033 withdrawn in Senate. (consideration: CR S8071) Floor 2013-11-18 0 Senate Considered by Senate. (consideration: CR S8071) Floor 2013-11-14 0 Senate Amendment SA 2033 proposed by Senator Reid. (consideration: CR S8026; text: CR S8026) To change the enactment date. Floor 2013-11-14 Senate amendment proposed (on the floor): Amendment SA 2033 proposed by Senator Reid.(consideration: CR S8026; text: CR S8026) Floor 93000 9 Library of Congress 2013-11-14 Senate amendment submitted Floor 91000 9 Library of Congress 2024 113 SAMDT 2022-02-08T17:32:01Z V000127 Sen. Vitter, David [R-LA] David Vitter R LA 2013-11-13T05:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2 2013-11-13 Senate amendment submitted Floor 91000 9 Library of Congress 2008 113 SAMDT 2022-02-08T17:32:01Z G000555 Sen. Gillibrand, Kirsten E. [D-NY] Kirsten Gillibrand D NY E. 2013-10-30T04:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2 2013-10-30 Senate amendment submitted Floor 91000 9 Library of Congress 2007 113 SAMDT 2022-02-08T17:32:01Z G000555 Sen. Gillibrand, Kirsten E. [D-NY] Kirsten Gillibrand D NY E. 2013-10-30T04:00:00Z Senate 113 HR House H 3204 Drug Quality and Security Act 2023-03-22T18:49:18Z 2 2013-10-30 Senate amendment submitted Floor 91000 9 Library of Congress Enrolled Bill https://www.govinfo.gov/content/pkg/BILLS-113hr3204enr/xml/BILLS-113hr3204enr.xml Placed on Calendar Senate 2013-11-05T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-113hr3204pcs/xml/BILLS-113hr3204pcs.xml Engrossed in House 2013-09-28T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-113hr3204eh/xml/BILLS-113hr3204eh.xml Introduced in House 2013-09-27T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-113hr3204ih/xml/BILLS-113hr3204ih.xml 2013-11-28T04:59:59Z https://www.govinfo.gov/content/pkg/PLAW-113publ54/uslm/PLAW-113publ54.xml Public Law 2013-11-27 Became Public Law No: 113-54. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.